Search results
Showing 16 to 30 of 380 results for lung cancer
In development Reference number: GID-TA11232 Expected publication date: 20 May 2026
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (HTG611)
Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules.
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)
Evidence-based recommendations for the adjuvant treatment of ALK-positive non-small-cell lung cancer in adults.
Show all sections
Topic prioritisation
Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.
Show all sections
Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.
In development Reference number: GID-TA11502 Expected publication date: 02 December 2026
Irreversible electroporation for treating primary lung cancer and metastases in the lung (HTG302)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for HTG302Show all sections
Sections for HTG302
Microwave ablation for primary or metastatic cancer in the lung (HTG609)
Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).
View recommendations for HTG609Show all sections
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.
This indicator covers the proportion of lung cancer cases for which a stage at diagnosis is recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG06
In development Reference number: GID-TA11405 Expected publication date: TBC
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.